Why the study?
Does the P2Y12 34C>T polymorphism increase the risk of neurological events in patients with symptomatic peripheral artery disease treated with clopidogrel?
Does the P2Y12 34C>T polymorphism increase the risk of neurological events in patients with symptomatic peripheral artery disease treated with clopidogrel?
The P2Y12 34C>T polymorphism is associated with an increased risk of ischemic cerebrovascular events in patients with peripheral artery disease treated with clopidogrel, suggesting a genetic basis for clopidogrel resistance.
Authors
No takes yet. Share an insight, caveat, or question.
May warrant caution with clopidogrel in PAD patients carrying the 34T allele; leaves open whether P2Y12 genotyping should guide therapy.
Ziegler et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: